rs907091 — IKZF3 IKZF3 miRNA Binding Region Variant

IKZF3 miRNA Regulation — When B-Cell Guardian Aiolos Is Silenced

IKZF3 encodes Aiolos, a zinc finger transcription factor in the Ikaros family that acts as a guardian of immune homeostasis. Aiolos is expressed throughout lymphocyte development and plays essential roles in B-cell maturation, plasma cell differentiation, and — crucially — suppression of aberrant autoimmune responses. Aiolos-deficient mice spontaneously develop a lupus-like syndrome¹¹ Aiolos-deficient mice spontaneously develop a lupus-like syndrome
Sun et al. J Immunol 2003; knockout mice produce anti-dsDNA antibodies and develop immune complex-mediated glomerulonephritis characteristic of human SLE, establishing that sufficient Aiolos expression is required to keep autoreactive B cells in check.

The rs907091 variant does not change the Aiolos protein itself — it sits in the 3' untranslated region²² 3' untranslated region
3'UTR — the section of mRNA after the stop codon that regulates mRNA stability, translation efficiency, and susceptibility to microRNA silencing of the IKZF3 transcript. The T allele at this position creates or enhances a binding site for miR-326³³ miR-326
A microRNA that silences target mRNAs by binding to complementary sequences in the 3'UTR and inhibiting translation or promoting mRNA degradation, the net effect being greater suppression of Aiolos protein output in T-allele carriers.

The Mechanism

Ghanbari et al. 2015⁴⁴ Ghanbari et al. 2015
Screening of 11,067 cardio-metabolic loci for miRNA binding site variants; rs907091 was one of only two variants validated by luciferase reporter assay as showing gain-of-function miRNA activity — the T allele enhanced miR-326 suppression of IKZF3 demonstrated through experimental reporter assays that the T allele at rs907091 enhances miR-326 activity at the IKZF3 3'UTR, amplifying post-transcriptional silencing. Because IKZF3 lies on the minus strand, the plus-strand T allele corresponds to an A substitution on the coding strand within the 3'UTR — this change creates a better match to the miR-326 seed sequence and increases miRNA-mediated repression.

The result is dose-dependent: each T allele adds another layer of miR-326 silencing, so TT homozygotes produce less Aiolos protein than CT heterozygotes, who in turn produce less than CC homozygotes.

Reduced Aiolos output has two major downstream consequences. First, it impairs B-cell maturation checkpoints⁵⁵ B-cell maturation checkpoints
Fedl et al. Nat Immunol 2024 — Aiolos co-operates with Ikaros to repress surrogate light-chain genes in small pre-B cells; without this repression step, ordered B-cell development is disrupted, allowing potentially autoreactive B cells to escape regulatory gates. Second, reduced Aiolos shifts the balance toward aberrant germinal center formation and spontaneous antibody production, as documented in Aiolos-null mice. In eosinophils, Aiolos controls CCR3 expression and tissue migration⁶⁶ CCR3 expression and tissue migration
Felton et al. Mucosal Immunol 2021; Aiolos-deficient eosinophils show reduced CCR3 surface expression and impaired chemotaxis, with blunted ERK/MAPK and actin polymerization responses to CCL11, making IKZF3 level relevant to eosinophil-driven allergic disease as well.

The Evidence

Population genetic studies in Chinese Han cohorts have directly associated rs907091 with systemic lupus erythematosus risk. Cai et al. PLoS One 2014⁷⁷ Cai et al. PLoS One 2014
310 SLE cases vs 341 healthy controls; four IKZF3 SNPs typed including rs907091 found that the CC genotype was significantly underrepresented in SLE patients relative to controls (p=0.001), and that the C allele itself was lower-frequency in cases (p=0.015). This protective effect is consistent with the mechanistic model: more Aiolos (CC genotype, lower miR-326 suppression) = better B-cell homeostasis = lower autoimmune risk.

A second case-control study by Ye et al. 2016⁸⁸ Ye et al. 2016
213 SLE patients vs 234 controls in Han Chinese from southern China; PCR-RFLP genotyping provided more granular analysis, showing that the CA (CT on plus strand) genotype specifically protected against SLE renal involvement (OR=0.59, 95% CI 0.35–0.98, p=0.043) and anti-SSB antibody production (OR=0.41, 95% CI 0.18–0.96, p=0.040). Anti-SSB (anti-La) antibodies are a marker of B-cell dysregulation in SLE, directly linking this variant to the Aiolos B-cell regulation pathway.

At a population level, the broader IKZF3–ZPBP2 chromosomal region reached genome-wide significance for SLE susceptibility in a multiracial GWAS of nearly 16,000 individuals⁹⁹ multiracial GWAS of nearly 16,000 individuals
Lessard et al. Am J Hum Genet 2012; p=3.48×10⁻¹⁰ for the IKZF3-ZPBP2 locus across European, African American, Asian, Hispanic, Gullah, and Amerindian populations, confirming that IKZF3 region variants are a replicated susceptibility signal beyond any single population.

The evidence is strongest in East Asian populations where rs907091 has been directly studied; the biological mechanism is well-established (Aiolos deficiency → autoimmunity in mice; T allele → enhanced miR-326 silencing → less Aiolos). Evidence from other ancestries and for RA specifically is less direct, and most studies focus on the closely linked rs2872507 at this locus.

Practical Actions

For TT homozygotes — who produce the least Aiolos and have the highest miR-326 suppression of IKZF3 — the primary actionable concern is elevated susceptibility to B-cell-mediated autoimmune disease, particularly SLE and related antibody-positive conditions. The most valuable actions are periodic autoantibody screening (ANA, anti-dsDNA) and prompt evaluation of any musculoskeletal or mucocutaneous symptoms suggesting early lupus. There is currently no approved intervention that specifically restores Aiolos expression, though lenalidomide and related IMiD drugs paradoxically degrade Aiolos via CRBN-mediated ubiquitination — these are not relevant as preventive treatments.

For eosinophilic or atopic conditions in carriers of the T allele, the connection to Aiolos-dependent eosinophil CCR3 expression and tissue recruitment provides biological rationale for reduced eosinophilic tissue inflammation, though direct clinical evidence linking rs907091 genotype to eosinophil counts in humans is not yet established.

Interactions

rs907091 sits within the 17q21 chromosomal region and is in partial linkage disequilibrium with rs2872507 (IKZF3 regulatory variant) and several ORMDL3/GSDMB SNPs at this locus. The rs2872507 A allele also confers autoimmune risk (RA, Crohn's, Graves') through a different regulatory mechanism affecting the ORMDL3-GSDMB locus. Carriers of risk alleles at both rs907091 and rs2872507 may face compounded IKZF3 functional impairment affecting distinct aspects of lymphocyte regulation.

Compound risk with PTPN22 rs2476601 (T-cell tolerance) is biologically plausible: PTPN22 R620W disrupts T-cell signaling thresholds while IKZF3 rs907091 TT impairs B-cell maturation oversight — two independent pathways converging on autoimmune susceptibility.